How does BIOC's PS Ratio compare to its peers?

BIOC is expensive based on its Price-To-Sales Ratio (2x) compared to the peer average (1.7x).

How does BIOC's PS Ratio compare vs other companies in the US Biotechs Industry?

BIOC is good value based on its Price-To-Sales Ratio (2x) compared to the US Biotechs industry average (10.9x).

What is BIOC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIOC is expensive based on its Price-To-Sales Ratio (2x) compared to the estimated Fair Price-To-Sales Ratio (0x).

What is the Fair Price of BIOC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate BIOC's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Biocept (Nasdaq:BIOC) - Stock Price, News & Analysis

BIOC Stock Overview

BIOC fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Revenue is forecast to grow 67.14% per year

Risk Analysis

Does not have a meaningful market cap ($3M)

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months

Has less than 1 year of cash runway

+ 2 more risks

Biocept, Inc. Competitors

Lipella Pharmaceuticals

NasdaqCM:LIPO

US$2.9m

Fresh2 Group

NasdaqCM:FRES

US$2.2m

Aptorum Group

NasdaqCM:APM

US$3.7m

AquaBounty Technologies

NasdaqCM:AQB

US$3.9m

Price History & Performance

Summary of all time highs, changes and price drops for Biocept
Historical stock prices
Current Share Price	US$1.02
52 Week High	US$27.00
52 Week Low	US$0.80
Beta	0.59
11 Month Change	-38.92%
3 Month Change	-13.56%
1 Year Change	-95.67%
33 Year Change	-99.28%
5 Year Change	-99.85%
Change since IPO	-100.00%

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13

Shareholder Returns

	BIOC	US Biotechs	US Market
7D	-3.8%	-10.3%	-2.1%
1Y	-95.7%	13.6%	29.6%

Return vs Industry: BIOC underperformed the US Biotechs industry which returned -4.2% over the past year.

Return vs Market: BIOC underperformed the US Market which returned 14.1% over the past year.

Price Volatility

Is BIOC's price volatile compared to industry and market?
BIOC volatility
BIOC Average Weekly Movement	20.9%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Stable Share Price: BIOC's share price has been volatile over the past 3 months.

Volatility Over Time: BIOC's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1997	50	Antonino Morales	biocept.com

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer.

Biocept, Inc. Fundamentals Summary

How do Biocept's earnings and revenue compare to its market cap?
BIOC fundamental statistics
Market cap	US$2.68m
Earnings (TTM)	-US$30.61m
Revenue (TTM)	US$1.36m

2.0x

P/S Ratio

-0.1x

P/E Ratio

Is BIOC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIOC income statement (TTM)
Revenue	US$1.36m
Cost of Revenue	US$15.66m
Gross Profit	-US$14.30m
Other Expenses	US$16.30m
Earnings	-US$30.61m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-11.66
Gross Margin	-1,054.09%
Net Profit Margin	-2,255.49%
Debt/Equity Ratio	181.4%

How did BIOC perform over the long term?

See historical performance and comparison

BIOC Stock Overview

Rewards

Risk Analysis

Biocept, Inc. Competitors

NasdaqCM:LIPO

US$2.9m

NasdaqCM:FRES

US$2.2m

NasdaqCM:APM

US$3.7m

NasdaqCM:AQB

US$3.9m

Price History & Performance

Recent News & Updates

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

New minor risk - Revenue size

Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)

Recent updates

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

New minor risk - Revenue size

Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)

Biocept, Inc. Announces Executive Changes

Biocept Expects to Receive Non-Compliance Notice Form Nasdaq

No longer forecast to breakeven

No longer forecast to breakeven

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Forecast to breakeven in 2025

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc. announced delayed 10-Q filing

Biocept Receives Non-Compliance Letter from Nasdaq

Biocept, Inc. Expands Commercial Offering of Cnside(Tm) Assay to Most Cancers That Metastasize to the Central Nervous System

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. announced delayed annual 10-K filing

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Investor sentiment improved over the past week

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)

Biocept, Inc. Implements Covid-19 Testing Program at Select California Community Colleges

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Consensus revenue estimates increase to US$37.5m

First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)

Price target decreased to US$12.00

Biocept enters COVID-19 testing partnership

Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients

New 90-day high: US$6.70

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

New 90-day high: US$6.23

Biocept, Inc. Enters into Laboratory Services Agreements with Independent Physician Associations

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept, Inc. Announces to Receives More Than 150,000 Samples for Covid-19 RT-PCR Testing

Biocept, Inc.'s Target Selector™ Liquid Biopsy Demonstrate High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations, earnings disappoint

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations, earnings disappoint